✦ LIBER ✦

Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

✍ Scribed by BAYEVER, ELIEL ;IVERSEN, PATRICK L. ;BISHOP, MICHAEL R. ;SHARP, J. GRAHAM ;TEWARY, HEMANT K. ;ARNESON, MARK A. ;PIRRUCCELLO, SAMUEL J. ;RUDDON, RAYMOND W. ;KESSINGER, ANNE ;ZON, GERALD ;ARMITAGE, JAMES O.

Book ID: 121431215
Publisher: Mary Ann Liebert
Year: 1993
Tongue: English
Weight: 897 KB
Volume: 3
Category: Article
ISSN: 1050-5261
DOI: 10.1089/ard.1993.3.383

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolonged Administration of Azacitidine

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

✍ Prebet, T.; Sun, Z.; Figueroa, M. E.; Ketterling, R.; Melnick, A.; Greenberg, P. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 687 KB

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

A Phase I/II Trial of Combination of PKC

A Phase I/II Trial of Combination of PKC412 and 5-azacytidine (AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

✍ Nazha, Aziz; Kantarjian, Hagop; Borthakur, Gautam; Kadia, Tapan; Faderl, Stefan; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 76 KB